Trump’s Controversial Tylenol-Autism Link: A Retrospective on a Contentious Announcement

In September 2025, former President Donald Trump sparked considerable debate with a reported announcement from his administration linking pregnant women’s use of Tylenol (paracetamol) to an increased risk of autism. This claim, which contradicted established medical guidelines, emerged shortly after a highly publicized memorial service for Charlie Kirk, who was fatally shot earlier that month.

The Tylenol-autism link was reportedly based on internal discussions and planned announcements, drawing immediate scrutiny from medical professionals and public health advocates. The proposed initiative also included exploring leucovorin as a potential autism treatment, adding another layer of controversy to the administration’s health policy stance.

The announcement followed Trump’s appearance at Kirk’s memorial in Arizona, where he delivered a wide-ranging address, praising Kirk as a ‘martyr’ and a ‘great American hero.’ The event, which saw Trump alongside figures like Elon Musk, blended eulogy with campaign rhetoric, as Trump veered into discussions about political opponents and his own policy initiatives, including the then-upcoming autism announcement. The memorial itself was described as a mix of spiritual revival and political rally, featuring emotional tributes and calls to action for government officials.

Erika Kirk, the widow of Charlie Kirk, offered a poignant moment at the memorial by publicly forgiving her husband’s shooter, stating it was ‘what Christ did, and it is what Charlie would do.’ The event also provided a platform for political figures like JD Vance, whose presence was seen by some as a strategic move in a potential 2028 presidential bid, blending populist messaging with a focus on economic nationalism.

阅读中文版 (Read Chinese Version)

Disclaimer: This content is aggregated from public sources online. Please verify information independently. If you believe your rights have been infringed, contact us for removal.